Delivery Order SPE2DB22D2006-SPE2DB24FW2FG

Award Date 7/25/24
Potential Completion Date 7/26/24
Potential Value $18K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award (SPE2DB20D2104/SPE2DB25FMGYE) was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,960.64, is for the delivery of RESTASIS 0.05% eye emulsion 60s. This is a firm fixed-price delivery order contract with a completion date of January 31, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,052.66 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract has an ultimate completion date of June 30, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor in the United States. The contract, valued at $2,362.76, is a Firm Fixed Price Delivery Order for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of October 7, 2024. Amerisourcebergen, through its Corporate Office Division, has been awarded this contract to provide essential pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,853.83 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has an ultimate completion date of September 10, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,471.20 Firm Fixed Price Delivery Order contract is for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription ophthalmic medication. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,276.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication. The contract has an ultimate completion date of November 3, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, with ID SPE2DB20D3505|SPE2DB22FT6J1, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,040.72 delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication, to support military and veteran healthcare programs. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,441.03 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion to support military healthcare programs. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of...
This federal contract award, valued at $10,247.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a completion date of May 19, 2022. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
This federal contract award, with ID SPE2DB20D1100|SPE2DB25FZ89F, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialized ophthalmic medication, with a ceiling value of $2,932.98 and a completion date of January 3, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D2006
    Indefinite Delivery Contract
  • SPE2DB22D2006-SPE2DB24FW2FG
    Delivery Order

This federal contract award SPE2DB22D2006|SPE2DB24FW2FG was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The $18,212.81 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion to support military and government healthcare programs. The contract has an ultimate completion date of July 26, 2024.

Amerisourcebergen Drug Corp is a major pharmaceutical distributor that specializes in supplying a wide range of medical products, prescription drugs, and healthcare solutions to federal agencies. The company holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing comprehensive pharmaceutical and medical supplies to military healthcare programs globally. This specific contract award does not have a set-aside designation, indicating open competition. By leveraging its extensive distribution capabilities, Amerisourcebergen supports the procurement of essential medical commodities for the benefit of military personnel, veterans, and other federal beneficiaries.

Generated 5/17/25, 9:54 AM